PROJECT SUMMARY/ABSTRACT
The ECOG-ACRIN Thoracic Integrated Translational Research Center (EA-ITSC) comprises a team of
accomplished researchers with a proven track record of collaborative work to improve outcomes for patients with
lung cancer. The EA-ITSC, funded in 2014 by the NCI (U10) at the same time as the formation of the National
Clinical Trials Network (NCTN), has played a major role in developing novel approaches for risk stratification,
molecular testing, and treatment of lung cancer. This group has also been responsible for guiding the
development of biomarker-driven clinical trials initiated by the ECOG-ACRIN Thoracic Malignancies Committee.
Our highly collaborative team approach includes sharing specimens across institutions, conducting pilot projects
that are of direct relevance to NCTN trials and guiding the translational research components of all newly
developed ECOG-ACRIN thoracic malignancies trials. Our overarching goal is to develop novel biomarkers to
enhance the efficacy of immunotherapy, overcome resistance to targeted agents and to identify combination
treatment approaches to enhance the efficacy of existing therapies in lung cancer within the context of the NCTN.
With this application, we propose to continue our research work with direct relevance to the NCTN, with the
following specific aims: 1) To develop genomic, epigenomic, and proteomics approaches to enhance biomarker
discovery efforts in ongoing and planned ECOG-ACRIN studies; 2) To conduct pilot studies on existing ECOG-
ACRIN and institutional lung cancer tumor specimens that will lead to prospective NCTN clinical trials; and 3) To
guide the development of translational research components of ECOG-ACRIN Thoracic trials and promote
collaborations with lung cancer SPORE and P01 institutions. The EA-ITSC will have a robust pilot projects
program that will invite participation from all the NCTN network groups, institutions with lung cancer SPORE and
P01 awards, to bring the best science to NCTN clinical trials.
Public Health Relevance Statement
PROJECT NARRATIVE
The ECOG-ACRIN Integrated Thoracic Malignancies Translational Sciences Center brings together a team of
outstanding researchers in both translational and clinical sciences to discover biomarkers and develop novel
treatment approaches for lung cancer within the National Clinical Trials Network.
NIH Spending Category
No NIH Spending Category available.
Project Terms
American College of Radiology Imaging NetworkAreaAwardBRAF geneBiological MarkersCenter for Translational Science ActivitiesChestClinicalClinical DataClinical SciencesClinical TrialsClinical Trials NetworkCollaborationsCombined Modality TherapyDetectionDevelopmentDiseaseEGFR inhibitionEarly DiagnosisEastern Cooperative Oncology GroupEnrollmentEpidermal Growth Factor ReceptorExcisionFundingGenomic TestingGenomicsGoalsGrantImmunologic MarkersImmunotherapyInstitutionLeadershipLungLung NeoplasmsMalignant neoplasm of lungMalignant neoplasm of thoraxMolecularMolecular AbnormalityMolecular AnalysisMutationNational Clinical Trials NetworkNon-Small-Cell Lung CarcinomaOperative Surgical ProceduresPatient-Focused OutcomesPatientsPilot ProjectsPlasmaPlasma CellsPlayPoly(ADP-ribose) Polymerase InhibitorPrecision Medicine InitiativePrecision therapeuticsPreventionProcessProteomicsROS1 geneRecurrenceResearchResearch PersonnelResidual NeoplasmResistanceRoleSTK11 geneScienceSelection for TreatmentsSpecimenTechnologyTestingTimeTranslational ResearchWorkbiomarker developmentbiomarker discoverybiomarker drivenbiomarker evaluationcell free DNAcheckpoint inhibitionchemotherapyclinical carecohortcompanion diagnosticsdriver mutationdrug developmentepigenetic markerepigenomicsimprovedimproved outcomeinnovationlung cancer screeningnext generationnovelnovel markernovel strategiespersonalized medicinephase 3 studyprogrammed cell death ligand 1programsprospectiverisk predictionrisk stratificationsmall cell lung carcinomatargeted agenttargeted treatmenttumor
No Sub Projects information available for 3UG1CA233259-06S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3UG1CA233259-06S1
Patents
No Patents information available for 3UG1CA233259-06S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3UG1CA233259-06S1
Clinical Studies
No Clinical Studies information available for 3UG1CA233259-06S1
News and More
Related News Releases
No news release information available for 3UG1CA233259-06S1
History
No Historical information available for 3UG1CA233259-06S1
Similar Projects
No Similar Projects information available for 3UG1CA233259-06S1